Komori
PhoenixBio (6190) · PolicyUpdate to the full-year impact of Topic 842

Planned Adoption of US GAAP Topic 842, “Leases”

First written in FY2022. 1 of 5 entries say "Achieved", first in FY2023-Q1. Latest entry: FY2023.

5entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2023-Q1OtherFY2023-Q2 – FY20232022: 320222023: 22023
Same theme, other companies
ASC 842 (Leases) Adoption MeasuresA theme 64 companies write about · 0 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2021: 2 of 11 companies on the "Worse" side.

4 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 64 companies compared. The sentences above are computed from all 64.
Full recordFilings, disclosures and news, newest first
  1. FY2023Update to the full-year impact of Topic 842Annual report

    「Certain overseas subsidiaries that apply U.S. GAAP have applied “Leases (Topic 842)” from the current consolidated fiscal year.」

    The full-year application of Topic 842 from the fiscal year ending March 2023 was confirmed, and the company recorded ¥124.631 million in right-of-use assets and other items. It stated that there was no impact on earnings.
  2. FY2023-Q3Update to the third-quarter impact of Topic 842Annual report

    「As a result, right-of-use assets increased by ¥2.114 million and other current liabilities increased by ¥2.359 million in the consolidated balance sheet for the third quarter. The change had no impact on profit or loss for the cumulative third-quarter period.」

    The company updated the increases in right-of-use assets and lease-related liabilities at the end of the third quarter for U.S. GAAP Topic 842, applied from the beginning of the fiscal year ending March 2023, and disclosed that there was no impact on earnings.
  3. FY2023-Q2Update to the second-quarter impact of Topic 842Annual report

    「As a result, on the consolidated balance sheet at the end of the second quarter, right-of-use assets increased by ¥9.286 million and other current liabilities increased by ¥10.364 million. This change had no impact on earnings for the cumulative second quarter.」

    The company updated the increases in right-of-use assets and lease-related liabilities at the end of the second quarter for U.S. GAAP Topic 842, applied from the beginning of the fiscal year ending March 2023, and disclosed that there was no impact on earnings.
  4. FY2023-Q1AchievedAnnual report

    「Certain overseas subsidiaries that apply U.S. GAAP have applied “Leases (Topic 842)” from the first quarter of the current consolidated fiscal year.」

    The company applied U.S. GAAP Topic 842, which had been scheduled for adoption from the fiscal year ending March 2023, from the beginning of the first quarter of the current consolidated fiscal year. It recorded ¥15.325 million in right-of-use assets and stated that there was no impact on earnings.
  5. FY2022First statedAnnual report

    「“Leases” (U.S. GAAP Topic 842) is scheduled to be applied from the fiscal year ending March 2023. The impact of applying “Leases” on the consolidated financial statements is currently being evaluated.」

    The company first disclosed that certain overseas subsidiaries related to U.S. GAAP Topic 842 were scheduled to apply it from the fiscal year ending March 2023 and that the impact was being evaluated.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Planned Adoption of US GAAP Topic 842, “Leases” | PhoenixBio Co.,Ltd. (6190) | Komori